Cancer diagnosis and prognosis may be revolutionized by artificial intelligence that can think like a pathologist while discovering patterns invisible to human observation. This breakthrough could accelerate personalized cancer treatment by identifying previously unknown cellular markers that predict patient outcomes and treatment responses. The SPARK system represents a new class of agentic AI that doesn't merely assist pathologists but conducts independent scientific reasoning about tissue samples. Unlike conventional AI tools that recognize pre-defined patterns, SPARK generates original biological hypotheses by analyzing cellular architecture, protein expression patterns, and tissue organization. The system successfully reproduced established pathological reasoning while identifying novel diagnostic parameters that correlate with patient prognosis and treatment sensitivity across multiple cancer types. This autonomous discovery capability could dramatically expand the toolkit available for precision oncology. The implications extend beyond efficiency gains to fundamental advances in understanding tumor biology. Traditional pathology relies on centuries-old visual assessment methods, while SPARK can process vast datasets to identify subtle cellular relationships that escape human detection. However, significant validation challenges remain before clinical deployment. The system's hypotheses require extensive verification in diverse patient populations, and regulatory frameworks for autonomous AI diagnosis are still evolving. Additionally, the 'black box' nature of AI decision-making raises questions about interpretability and physician trust. While promising, this represents early-stage research rather than a ready-to-deploy clinical tool. The technology's true impact will depend on rigorous validation studies and successful integration with existing pathology workflows, potentially transforming cancer care from reactive treatment to predictive intervention.